HRP20151312T1 - Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom - Google Patents
Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom Download PDFInfo
- Publication number
- HRP20151312T1 HRP20151312T1 HRP20151312TT HRP20151312T HRP20151312T1 HR P20151312 T1 HRP20151312 T1 HR P20151312T1 HR P20151312T T HRP20151312T T HR P20151312TT HR P20151312 T HRP20151312 T HR P20151312T HR P20151312 T1 HRP20151312 T1 HR P20151312T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacological agent
- seq
- mast cell
- cell degranulation
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99267807P | 2007-12-05 | 2007-12-05 | |
| EP08859906.3A EP2229185B8 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory agent |
| PCT/US2008/085280 WO2009076105A2 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151312T1 true HRP20151312T1 (hr) | 2016-03-11 |
Family
ID=40756064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151312TT HRP20151312T1 (hr) | 2007-12-05 | 2008-12-02 | Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8080518B2 (enExample) |
| EP (1) | EP2229185B8 (enExample) |
| JP (1) | JP5520230B2 (enExample) |
| CN (1) | CN101970011B (enExample) |
| AU (1) | AU2008335490B2 (enExample) |
| BR (1) | BRPI0820912B1 (enExample) |
| DK (1) | DK2229185T3 (enExample) |
| ES (1) | ES2555524T3 (enExample) |
| HR (1) | HRP20151312T1 (enExample) |
| HU (1) | HUE027216T2 (enExample) |
| PL (1) | PL2229185T3 (enExample) |
| PT (1) | PT2229185E (enExample) |
| SI (1) | SI2229185T1 (enExample) |
| WO (1) | WO2009076105A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| ES2804424T3 (es) * | 2006-07-11 | 2021-02-08 | Nono Inc | Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre |
| US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| JP6005357B2 (ja) * | 2008-05-16 | 2016-10-12 | ノノ インコーポレイテッド | てんかんの治療 |
| AU2009288088B2 (en) * | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
| BRPI1010718A2 (pt) | 2009-06-10 | 2016-03-15 | Nono Inc | sistemas modelo e regimes de tratamento para tratar doença neurológica. |
| AU2010259986B2 (en) | 2009-06-10 | 2015-04-02 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| WO2011038397A2 (en) * | 2009-09-28 | 2011-03-31 | Duke University | Peptide adjuvants, vaccines, and methods of use |
| JP2013527834A (ja) * | 2010-03-29 | 2013-07-04 | マサチューセッツ インスティテュート オブ テクノロジー | 抗炎症因子 |
| EP2580233B1 (en) * | 2010-06-10 | 2016-08-10 | Indiana University Research And Technology Corporation | Materials and method for suppressing inflammatory and neuropathic pain |
| EP2616094B1 (en) * | 2010-08-12 | 2017-11-08 | NoNO Inc. | Treatment of penetrative injury to the brain |
| KR102046830B1 (ko) * | 2011-05-13 | 2019-11-20 | 코벤하븐스 유니버시테트 | 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제 |
| KR102022116B1 (ko) | 2011-06-24 | 2019-09-18 | 노노 인코포레이티드 | 허혈에 대한 psd-95 억제제와의 조합 요법 |
| US9730921B2 (en) | 2012-03-27 | 2017-08-15 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| HUE043820T2 (hu) * | 2012-11-28 | 2019-09-30 | Nono Inc | Liofilizált TAT-NR2B9c készítmény |
| WO2014150350A1 (en) * | 2013-03-15 | 2014-09-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| ES2600488T3 (es) | 2014-05-23 | 2017-02-09 | Ares Trading S.A. | Composición farmacéutica líquida |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| WO2016049280A1 (en) * | 2014-09-24 | 2016-03-31 | Memorial Sloan Kettering Cancer Center | mTORC1 MODULATION |
| WO2019061395A1 (zh) * | 2017-09-30 | 2019-04-04 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1159418A2 (en) * | 1998-12-11 | 2001-12-05 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| DE60026313D1 (de) * | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| MXPA02001857A (es) * | 1999-08-24 | 2003-07-14 | Cellgate Inc | Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales. |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) * | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| AU2002356511A1 (en) * | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| US20060276455A1 (en) * | 2003-02-13 | 2006-12-07 | Lindsberg Perttu J | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| EP2801366A3 (en) * | 2004-09-02 | 2015-04-29 | Cognosci, Inc. | Improved apo E analogs and methods for their use |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| WO2009006611A1 (en) * | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| EP2178549B1 (en) * | 2007-07-26 | 2016-09-14 | Revance Therapeutics, Inc. | Antimicrobial peptide and compositions thereof |
| ES2328776B1 (es) * | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| AU2010259986B2 (en) | 2009-06-10 | 2015-04-02 | Nono Inc. | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
-
2008
- 2008-11-26 US US12/323,915 patent/US8080518B2/en active Active
- 2008-12-02 PL PL08859906T patent/PL2229185T3/pl unknown
- 2008-12-02 ES ES08859906.3T patent/ES2555524T3/es active Active
- 2008-12-02 PT PT88599063T patent/PT2229185E/pt unknown
- 2008-12-02 SI SI200831555T patent/SI2229185T1/sl unknown
- 2008-12-02 DK DK08859906.3T patent/DK2229185T3/en active
- 2008-12-02 CN CN2008801261196A patent/CN101970011B/zh not_active Expired - Fee Related
- 2008-12-02 HU HUE08859906A patent/HUE027216T2/en unknown
- 2008-12-02 HR HRP20151312TT patent/HRP20151312T1/hr unknown
- 2008-12-02 JP JP2010537016A patent/JP5520230B2/ja not_active Expired - Fee Related
- 2008-12-02 AU AU2008335490A patent/AU2008335490B2/en not_active Ceased
- 2008-12-02 EP EP08859906.3A patent/EP2229185B8/en active Active
- 2008-12-02 WO PCT/US2008/085280 patent/WO2009076105A2/en not_active Ceased
- 2008-12-02 BR BRPI0820912-0A patent/BRPI0820912B1/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101970011A (zh) | 2011-02-09 |
| AU2008335490A1 (en) | 2009-06-18 |
| JP2011506328A (ja) | 2011-03-03 |
| BRPI0820912A2 (pt) | 2018-07-17 |
| AU2008335490B2 (en) | 2013-08-22 |
| WO2009076105A3 (en) | 2010-01-07 |
| CN101970011B (zh) | 2013-04-24 |
| JP5520230B2 (ja) | 2014-06-11 |
| DK2229185T3 (en) | 2016-01-11 |
| EP2229185A2 (en) | 2010-09-22 |
| EP2229185B8 (en) | 2016-12-21 |
| ES2555524T3 (es) | 2016-01-04 |
| BRPI0820912B1 (pt) | 2022-05-24 |
| PL2229185T3 (pl) | 2016-03-31 |
| SI2229185T1 (sl) | 2016-02-29 |
| EP2229185B1 (en) | 2015-10-07 |
| WO2009076105A2 (en) | 2009-06-18 |
| US20090176713A1 (en) | 2009-07-09 |
| EP2229185A4 (en) | 2011-11-23 |
| PT2229185E (pt) | 2016-01-26 |
| US8080518B2 (en) | 2011-12-20 |
| HUE027216T2 (en) | 2016-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151312T1 (hr) | Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom | |
| JP2011506328A5 (enExample) | ||
| EA200971130A1 (ru) | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний | |
| HRP20151148T1 (hr) | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja | |
| JP2014527040A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| BRPI0508843A (pt) | composto ou sal do mesmo, método para preparar um composto ou um sal do mesmo, método de tratamento e/ou profilaxia de doença, e, composição farmacêutica | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| Ianzer et al. | Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? New insights from proline-rich peptides of Bothrops jararaca | |
| NZ597554A (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
| EP2687220A3 (en) | Treatment of inflammatory diseases using placental stem cells | |
| WO2011047097A3 (en) | Inhibition of trem receptor signaling with peptide variants | |
| JP2014050390A5 (enExample) | ||
| MX388822B (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| JP2019513752A5 (enExample) | ||
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| JP2010536714A5 (enExample) | ||
| HRP20210013T1 (hr) | Stabilni polipeptidi koji se vezuju za ljudski komplement c5 | |
| CN102186496A (zh) | 治疗肾功能紊乱的组合物和方法 | |
| Lima et al. | Perinatal asphyxia and brain development: mitochondrial damage without anatomical or cellular losses | |
| HRP20160385T1 (hr) | Pripravci za prevenciju i liječenje neurodegenerativnih bolesti | |
| JP2009533355A5 (enExample) | ||
| Horvath et al. | Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion | |
| ECSP077224A (es) | Nuevos usos de derivados de imidazotriazinona 2-fenil sustituidos |